
Chronology of Discoveries
A partial chronology of our most important discoveries:
|
1985 |
Olavi Kajander observes nanoscale particles in vitro, forming a community, as contaminants in mammalian cell cultures. He surmises that they may be alive. Without training, others fail at culturing due to the nanoscopic size and slow growth. |
|
1986 |
Kajander observes that some of the particles he found earlier appear to have a hard surface. |
|
1987 |
Kajander discovers the unique calcific particles in human blood. |
|
1988 |
Kajander takes first electron microscope pictures of nanobacteria and develops polyclonal antibodies to detect them. |
|
1990 |
Kajander files for patents for nanobacteria, plus culturing and antibody methods. |
|
1991 |
Kajander develops new monoclonal antibodies to detect nanobacteria. |
|
1992 |
Kajander is awarded a patent for nanobacteria and nanobacterial detection methods. |
|
1992 |
Kajander discovers that nanobacteria make mineralized "igloo-like" structures, explaining the hard surfaces observed earlier. |
|
1992 |
Kajander et al. publish one of the first abstracts on blood nanobacteria, Nanobacterium sanguineum. |
|
1992 |
Kajander optimizes the culturing process by developing a unique medium that makes nanobacteria grow quickly and produces colonies on solid media. |
|
1993 |
Kajander and his Finnish company Nanobac OY optimize methods for detecting nanobacteria antigen as a prototype for the commercial methods used today. |
|
1997 |
Gary Mezo independently develops his NanobacTX, a pharmaceutical compound to reverse heart disease. Mezo then starts NanobacLabs Pharmaceuticals, the precursor to his Nanobac Pharmaceuticals, Inc. the US publicly traded company. Mezo later buys Kajander's Finnish Company Nanobac OY and the patents from the Finnish Government and hires the scientist Olavi Kajander, MD, PhD. |
|
1997 |
Kajander et al. announces discovery of potential nanobacteria contamination in antibody products. |
|
1997 |
Kajander, et al announce discovery that nanobacteria replicate in rabbits, fulfilling another part of Koch’s postulate. |
|
1998 |
Kajander announces discoveries & applies for a patent which was later allowed by European and American agencies. |
|
1998 |
Kajander announces discovery of nanobacteria in kidney stones. The story is covered by journals and news services worldwide. |
|
1998 |
Kajander announces discovery of nanobacteria in periodontal disease plaque and dental pulp stones. |
|
1999 |
László Puskás, PhD (University of Szeged) collaborates with Kajander to detect nanobacteria in atherosclerotic plaques and submits his research findings to prominent scientific journals but has difficulty getting his new findings published. |
|
|
|
|
1999 |
Nanobac Oy, a Finnish start-up company, begins using diagnostic tests for diagnosing nanobacteria in research patients with heart and kidney disease. |
|
|
|
|
1999-2000 |
Critic's investigation into Kajander's nanobacterial research shows validity of Kajander's research & methods. |
|
2000 |
Garcia-Cuerpo et al. fulfill & prove Koch's postulates for proving nanobacteria as infectious disease causing agent. |
|
2000 |
University of Illinois' Hjelle & Miller announce discovery of nanobacteria in Polycystic Kidney Disease (PKD). |
|
2001 |
Kajander announces detection of live nanobacteria found as contaminants in sterilized viral vaccines as reported by Vaccines Today and New Scientist. |
|
2001 |
First Worldwide Nanobacteria Symposium held at University of Kuopio, Finland brings Mezo, Kajander & many other nanobacteria researchers together for the first time. |
|
2002 |
Clinical study reports on Mezo's NanobacTX by cardiologists, begin to show first formal independent results that severe heart disease patients have sustained substantial reductions in heart disease measurements, symptoms and markers after treatment with NanobacTX. |
|
2002 |
Rasmussen duplicates Laszlo Puskas' research work, finding nanobacteria in atherosclerotic plaque. |
|
2002 |
Kajander announces discovery of contamination of immune gamma globulin products with nanobacteria. |
|
2002 |
Nanobac Pharmaceuticals' CEO & Founder, Gary Mezo designs and begins the first IRB-Monitored cardiovascular study on NanobacTX and Tampa cardiologist, Benedict Maniscalco, MD, FACC independently conducts the study. |
|
2003 |
Kerner et al. announce discovery of nanobacteria entities that replicate in bacteria-like ways in polluted river water. |
|
2003 |
Cardiology researcher Maniscalco completes Mezo's first clinical trial of NanobacTX and announces preliminary significant reductions in coronary artery calcium scores and other markers of heart disease that shows the first structural and functional reversal of Coronary Artery Heart Disease. |
|
2003 |
Olavi Kajander, Benedict Maniscalco and Gary Mezo publish their Unified Theory of Atherogenesis & Treatment based on nanobacterial infection, calcification, inflammation & swelling. |
|
2003 |
Roland Sedivy and Walter B. Battistutti announce discovery of nanobacteria in calcified adenocarcinomas in ovarian cancer. |
|
2004 |
Madhu Khullar, S. K. Sharma, S. K. Singh, Pratibha Bajwa, Farooq A. Sheikh, Vandana Relan and Meera Sharma announce that they have isolated nanobacteria from human kidney stones. |
|
2004 |
The Sino-Finland Nanobacteria Co-Operation Center, an international institute devoted to the study of nanobacteria is started by the University of Kuopio in Finland and the Second Affiliated Hospital Central South University, Changsha, China. |
|
2004 |
Jelic, Malas, Groves et al announce independent discovery of nanobacteria in the heart valve of end-stage diabetes patient. |
|
2004 |
Mayo Clinic's John Lieske, MD, PhD et al. announce that they have found RNA-synthesizing nanobacteria organisms in cardiovascular disease. |
|
2004 |
Stephen Epstein, MD, PhD (NIH Director of cardiovascular research & Director of CV Research at Washing Hospital Medical Center) and Jianhui Zhu, PhD present at the American Heart Assn. Annual Meeting their discovery of a correlation between high levels of coronary artery calcification and the presence of nanobacteria, They also establish Nanobacterial antigen & antibodies are a higher heart disease risk-factor than is homocysteine or cholesterol. Epstein's studies were done using Mezo's nanobacteria rapid test that can serve as a tool for predicting heart disease risk. |
|
2005 |
NASA's Nanobacteria Research Center announces that nanobacteria grow faster in microgravity which may explain increased kidney stone formation in astronauts during space flights. |
|
2005 |
Wen, Y., Kajander, et al annouce that they have detected nanobacteria in serum, bile, and gallbladder mucosa of patients with cholecystolithiasis (gallstones). |
|
2005 |
Cleveland Clinic's Daniel Shoskes publishes his Urobac study in The Journal of Urology showing our Urobac is effective in reversing chronic prostatitis (CP-CPPSIII), chronic pelvic pain syndrome (CPPS) and prostate stones. |
|
2006
2006- |
Tsurumoto, Matsumoto, et al publish their detection of nanobacteria in human arthritic synovial joint fluids.
Our nanobacterial research continues at scores of universities & respected research facilities Worldwide. NANOBIOTECH PHARMA exclusively develops all Intellectual Property relating to Nanobacterial Nanobiotics, therapies and treatments, including but limited to: NanobacTX, Urobac, & Dermabac. |

